

While Congress also amended section “824(a) to add to the current bases for denial, revocation, or suspension of registration a finding that registration would be inconsistent with the public interest on the grounds specified in [section] 823, which will include consideration of the new factors added by” the amendment, *id.* at 266–67, Congress did not otherwise alter the text of section 824(a), which makes clear that the various paragraphs of this provision are findings, each of which provides an independent and adequate ground to support agency action against a registration, and not discretionary factors to be considered by the Agency. Indeed, Respondent points to nothing in the language of section 824 or the CSA’s legislative history to support his position, which would fundamentally alter the scope of the Agency’s authority under section 824.

I therefore reject Respondent’s contentions. Based on the ALJ’s finding

that Respondent is not currently authorized to dispense controlled substances in Mississippi, the State in which he holds the DEA registration at issue in this proceeding, I will adopt the ALJ’s recommended order that I revoke his registration.

Order

Pursuant to the authority vested in me by 21 U.S.C. 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. AF2451261 issued to Arnold E. Feldman, M.D., be, and it hereby is, revoked. This *Order* is effective immediately.⁹

Dated: November 13, 2017.

Robert W. Patterson,
Acting Administrator.

[FR Doc. 2017–25287 Filed 11–21–17; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR Docket	Published
Almac Clinical Services Incorp (ACSI)	82 FR 37114	August 8, 2017.
Stepan Company	82 FR 41054	August 29, 2017.
Fresenius Kabi USA, LLC	82 FR 41053	August 29, 2017.
Cambrex Charles City	82 FR 41055	August 29, 2017.
Spex Certiprep Group, LLC	82 FR 42120	September 6, 2017.
Akorn, Inc	82 FR 42117	September 6, 2017.
Fisher Clinical Services, Inc	82 FR 42121	September 6, 2017.
Siegfried USA, LLC	82 FR 42117	September 6, 2017.
Mylan Pharmaceuticals, Inc	82 FR 42120	September 6, 2017.
KVK-Tech, Inc	82 FR 42119	September 6, 2017.
Cerilliant Corporation	82 FR 43404	September 15, 2017.
Unither Manufacturing LLC	82 FR 43571	September 18, 2017.
Mylan Pharmaceuticals, Inc	82 FR 43572	September 18, 2017.
Catalent Centers, LLC	82 FR 43569	September 18, 2017.
Specgx LLC	82 FR 43571	September 18, 2017.
Sharp Clinical Services, Inc	82 FR 43572	September 18, 2017.
Cody Laboratories, Inc	82 FR 45612	September 29, 2017.
Bellwyck Clinical Services	82 FR 45613	September 29, 2017.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical

security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed persons.

Dated: November 16, 2017.

Demetra Ashley,
Acting Assistant Administrator.

[FR Doc. 2017–25284 Filed 11–21–17; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Linda M. Shuck, D.O.; Decision and Order

On July 25, 2017, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration, issued an Order to Show Cause to Linda M. Shuck (Registrant), of Dobson, North Carolina. The Show Cause Order proposed the revocation of Registrant’s Certificate of Registration, on the ground that she

⁹ While the Mississippi Board Order was based on the Louisiana Board’s Order, as noted in the former Acting Administrator’s Decision and Order which revoked Respondent’s Louisiana registration, the Louisiana Board found proved the sixth charge of the Administrative Complaint in that proceeding, in

that Respondent violated state law by “[p]rescribing, dispensing, or administering legally controlled substances or any dependency-inducing medication without legitimate medical justification thereof or in other than a legal or legitimate manner.” See 82 FR at 39618 n.8 (2017); see also

Mot. for Summ. Disp., Appendix B, at 22, 24 (Louisiana Board Order at 12, 14). For the same reasons as those cited by the former Acting Administrator, I find that the public interest necessitates that this Order be effective immediately. See also 21 CFR 1316.67.

“do[es] not have authority to handle controlled substances in the State of North Carolina, the [S]tate in which [she is] registered with the” Agency. GX 2, at 1 (citing 21 U.S.C. 823(f) and 824(a)(3)).

As to the jurisdictional basis for the proceeding, the Show Cause Order alleged that Registrant is the holder of a practitioner’s registration with authority in schedules II through V, under Certificate of Registration No. BP4154023, at the registered location of Carolina Heart Care, 651 S. Main Street, Dobson, North Carolina. *Id.* The Order further alleged that this registration “expires . . . on February 28, 2018.” *Id.*

As to the substantive ground for the proceeding, the Show Cause Order alleged that on June 23, 2017, the North Carolina Medical Board suspended Registrant’s medical license for six months. *Id.* The Order alleged that because of the Board’s action, Registrant is “without authority to handle controlled substances in . . . North Carolina, the [S]tate in which [she is] registered,” and that as a consequence, her registration is subject to revocation. *Id.* at 1–2 (citing cases).

The Show Cause Order notified Registrant of her right to request a hearing on the allegations or to submit a written statement while waiving her right to a hearing, the procedure for electing either option, and the consequence for failing to elect either option. *Id.* at 2 (citing 21 CFR 1301.43). In addition, the Show Cause Order notified Registrant of her right to submit a corrective action plan under 21 U.S.C. 824(c)(2)(C). *Id.* at 2–3.

On August 1, 2017, a DEA Special Agent assigned to the Charlotte District Office personally served the Show Cause Order on Registrant. GX 3, at 1–2 (Declaration of Special Agent). In a letter dated August 3, 2017, Registrant stated that she was “aware of the current law regarding [her] DEA Certificate” and that she did “not wish to have a hearing on the issue.” GX 4. Registrant further stated that her “medical license is suspend[ed] until 12–23–2017” and that she “will reapply for [her] DEA certification after [her] suspension is completed.” *Id.*

On September 8, 2017, the Government submitted a Request for Final Agency Action. Therein, the Government seeks the revocation of Registrant’s registration. As support for the proposed action, the Government submitted various exhibits, including a Consent Order entered into by Registrant and the North Carolina Medical Board on May 23, 2017. *See* GX3A, at 8.

Based on Registrant’s letter of August 3, 2017, I find that Registrant has waived her right to a hearing on the allegations of the Show Cause Order. 21 CFR 1301.43. I therefore issue this Decision and Order based on relevant evidence submitted by the Government. I make the following findings.

Findings

Registrant is the holder of DEA Certificate of Registration No. BP4154023, pursuant to which she is authorized to dispense controlled substances in schedules II through V, at the registered address of Carolina Heart Care, 651 S. Main St., Dobson, North Carolina. GX 1. Registrant is also the holder of DATA-Waiver Identification No. XP4154023, pursuant to which she is authorized to prescribe schedule III through V “narcotic drug[s] approved by the Food and Drug Administration specifically for use in maintenance or detoxification treatment” to up to 100 patients. GX 1; *see also* 21 CFR 1306.04(c).

Registrant is also the holder of a license to practice medicine and surgery issued by the North Carolina Medical Board. However, on May 23, 2017, Registrant entered into a Consent Order with the Board. GX 3, Appendix A, at 8. The Board’s Order found that in September 2014, Registrant and the Board had entered a previous Consent Order “based on findings that [she] had failed to conform to the standards of acceptable and prevailing medical practice in her care of five patients that she treated for chronic pain.” *Id.* at 2. The Board further found that while Registrant “underwent the required [comprehensive professional] assessment, [she] still has failed to complete any remediation recommended by the assessment center in a timely manner.” *Id.*

The Board’s Order also found that, in April 2016, it had received information regarding Registrant’s prescribing of opiates to four patients, including one who died due to “opioid toxicity.” *Id.* The Board further found that “an independent medical expert” had reviewed the medical records of the four patients and opined that Registrant’s “diagnosis, treatment, and overall care in all four . . . cases failed to conform to the standards of acceptable and prevailing medical practice in North Carolina.” *Id.*

Finally, the Board found that, “[o]n December 6, 2016, [Registrant] entered into an Interim Partial Non-Practice Agreement restricting her prescribing of all controlled substances.” *Id.* at 3. The Board further found that Registrant issued controlled substance

prescriptions to patients in violation of the Interim Partial Non-Practice Agreement. *Id.*

With respect to her “care and treatment of” the four patients, the Board concluded as a matter of law that Registrant “fail[ed] to conform to the standards of acceptable and prevailing medical practice.” *Id.* at 4 (citing N.C. Gen. Stat. SEC. 90–14(a)(6)). The Board also concluded as a matter of law that Registrant’s “issuance of controlled substance prescriptions in violation of a restriction contained in the December 2016 Interim Partial Non-Practice Agreement . . . constitutes unprofessional conduct.” *Id.* (citing N.C. Gen. Stat. SEC. 90–14(a)(6)).

The Board and Registrant agreed to resolve the matter by suspending her medical license for a period of six months “from June 23, 2017[] until December 23, 2017.” *Id.* at 5. While the Board and Registrant agreed that she “may return to the active practice of medicine on December 24, 2017, subject to the provisions contained in this . . . Order,” the provisions include that she “shall not prescribe controlled substances except for a patient who has been admitted to a hospital where [she] has active clinical privileges.” *Id.* The provisions also include that “[o]nce the patient has been discharged, [she] shall not prescribe controlled substances for those patients who received such medications pursuant to” the above provision. *Id.* at 6.

Moreover, Registrant’s ability to resume practicing medicine is also subject to the condition that she “complete a five . . . day board certification review course in Internal Medicine.”¹ *Id.* Thus, while the suspension may expire in less than six weeks, it is far from certain that she will be able to resume practicing medicine (even subject to the limitations on her authority to prescribe), and absent evidence that she has completed the board certification review course, the restriction on her ability to resume practicing takes on the characteristic of a suspension of indefinite duration. Based on the above, I find that Registrant is currently without authority

¹ According to the online records of the North Carolina Medical Board, of which I take official notice, the suspension of Registrant’s medical license remains in effect as of the date of this Decision and Order. *See* 5 U.S.C. 556(e). Registrant may dispute this finding by filing a properly supported motion for reconsideration within 10 business days of the date of this Order with the Office of the Administrator. Registrant may also provide evidence that she has completed the five-day board certification review course. Registrant must serve a copy of any such motion on the Government.

to dispense controlled substances under the laws of the State of North Carolina.

Discussion

Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized to suspend or revoke a registration issued under section 823, “upon a finding that the Registrant . . . has had his State license . . . suspended [or] revoked . . . by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances.” Also, DEA has held repeatedly that the possession of authority to dispense controlled substances under the laws of the State in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining a practitioner’s registration. *See, e.g., James L. Hooper*, 76 FR 71371 (2011), *pet. for rev. denied*, 481 Fed Appx. 826 (4th Cir. 2012); *Frederick Marsh Blanton*, 43 FR 27616 (1978).

This rule derives from the text of two provisions of the CSA. First, Congress defined “the term ‘practitioner’ [to] mean[] a . . . physician . . . or other person licensed, registered or otherwise permitted, by . . . the jurisdiction in which [s]he practices . . . to distribute, dispense, [or] administer . . . a controlled substance in the course of professional practice.” 21 U.S.C. 802(21). Second, in setting the requirements for obtaining a practitioner’s registration, Congress directed that “[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which [s]he practices.” 21 U.S.C. 823(f). Because Congress has clearly mandated that a physician possess state authority in order to be deemed a practitioner under the Act, DEA has held that revocation of a practitioner’s registration is the appropriate sanction whenever she is no

longer authorized to dispense controlled substances under the laws of the State in which she practices medicine. *See, e.g., Calvin Ramsey*, 76 FR 20034, 20036 (2011); *Sheran Arden Yeates, M.D.*, 71 FR 39130, 39131 (2006); *Dominick A. Ricci*, 58 FR 51104, 51105 (1993); *Bobby Watts*, 53 FR 11919, 11920 (1988); *see also Hooper v. Holder*, 481 Fed. Appx. at 828.

As a consequence of the Consent Order which Registrant entered into with the Board, she is not currently authorized to dispense controlled substances in North Carolina, the State in which she is registered with the Agency. Because the CSA makes clear that the possession of authority to dispense controlled substances under the laws of the State in which a practitioner engages in professional practice is a fundamental condition for both obtaining and maintaining a practitioner’s registration, it is of no consequence that the suspension is of a finite duration. *See Hooper v. Holder*, 481 F. App’x at 828 (upholding revocation of a physician’s registration as based on a reasonable interpretation of the CSA, notwithstanding that the physician’s medical license was subject to a suspension of known duration); *see also James L. Hooper*, 76 FR 71371, 71371–72 (2011). Rather, what matters for the purposes of the CSA is that Registrant is not currently authorized to dispense controlled substances in North Carolina. *See Hooper*, 76 FR at 71371 (quoting *Anne Lazar Thorn*, 62 FR 12847, 12848 (1997) (“the controlling question . . . is whether the Respondent is currently authorized to handle controlled substances in the state’’)). Indeed, it is by no means clear that Registrant will even be able to resume the practice of medicine following the ending date of the suspension given the requirement that she complete the required five-day board certification review course.²

Therefore, she is not entitled to maintain her registration in that State. Accordingly, I will order that her registration and her DATA-Waiver Identification number be revoked.

Order

Pursuant to the authority vested in me by 21 U.S.C. 824(a) and 28 CFR 0.100(b), I order that DEA Certificate of Registration No. BP4154023, issued to Linda M. Shuck, be, and it hereby is, revoked. I further order that DATA-Waiver Identification No. XP4154023, issued to Linda M. Shuck, be, and it hereby is, revoked. This order is effective immediately.³

Dated: November 13, 2017.

Robert W. Patterson,
Acting Administrator.

[FR Doc. 2017–25286 Filed 11–21–17; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration as bulk manufacturers of various classes of schedule I and II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

Company	FR Docket	Published
Cayman Chemical Company	82 FR 34691	July 26, 2017.
AMRI Rensselaer, Inc	82 FR 34695	July 26, 2017.
Organic Consultants, Inc	82 FR 34696	July 26, 2017.
Isosciences, LLC	82 FR 35546	July 31, 2017.
Cody Laboratories, Inc	82 FR 41054	August 29, 2017.
Noramco, Inc	82 FR 41055	August 29, 2017.
Stepan Company	82 FR 42119	September 6, 2017.

² Indeed, as found above, even if she completes the course and returns to practice, under the Consent Order, she is prohibited from prescribing controlled substances outside of a hospital where she “has active clinical privileges.” GX 3, Appendix A, at 5. As this revocation does not impose any time

bar on Registrant’s ability to reapply, she can apply for a new registration upon being allowed to return to practice.

³ Based on the North Carolina Board’s findings that Registrant prescribed controlled substances in

violation of the Interim Partial Non-Practice Agreement, I find that the public interest necessitates that this Order be effective immediately. 21 CFR 1316.67.